# EDGAR Filing Document

**Accession Number:** 0001693011
**File Stem:** 0000000000-25-006066
**Filing Date:** 2025-6
**Character Count:** 3160
**Document Hash:** 132c9cccaa497f51fa6f8313576ae44f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-006066.hdr.sgml**: 20250811

**ACCESSION NUMBER**: 0000000000-25-006066

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250609

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inozyme Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001693011
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475129768
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 005-91586

**BUSINESS ADDRESS:**
- **STREET 1:** 321 SUMMER STREET
- **STREET 2:** SUITE 400
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 857-330-4340

**MAIL ADDRESS:**
- **STREET 1:** 321 SUMMER STREET
- **STREET 2:** SUITE 400
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Inozyme Pharma, LLC
- **DATE OF NAME CHANGE:** 20161222
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-25-121809

## Text-Extract

```

                                                           June 9, 2025

Jamie Leigh
Partner
Cooley LLP
3 Embarcadero Center
20th Floor
San Francisco, CA 94111-4004

       Re: Inozyme Pharma, Inc.
           SC TO-T filed June 2, 2025, amended June 4, 2025
           Filed by Incline Merger Sub, Inc. and Biomarin Pharmaceutical Inc.
           File No. 005-91586
Dear Jamie Leigh:

       We have reviewed your filing and have the following comments. In some of
our
comments, we may ask you to provide us with information so we may better
understand your
disclosure.

        Please respond to these comments by providing the requested information
or advise us
as soon as possible when you will respond. If you do not believe our comments
apply to your
facts and circumstances, please tell us why in your response.

       After reviewing your response to these comments, we may have additional
comments.

Schedule TO-T
Offer to Purchase - Background of the Offer, page 28

1.     Please revise your disclosure to describe the preliminary discussions
Parent carried
       out in 2024 with Inozyme, including the individuals involved and the
setting of such
       discussions.
2.     Describe the negotiations of the tender and support agreements. In
addition, disclose
       the name of the shareholders with whom you negotiated the agreements
and, if
       different, those with whom you entered into agreement.
        We remind you that the filing persons are responsible for the accuracy
and adequacy
of their disclosures, notwithstanding any review, comments, action or absence
of action by
the staff.
 June 9, 2025
Page 2

       Please direct any questions to Daniel Duchovny at 202-551-3619.

                                                         Sincerely,

                                                         Division of
Corporation Finance
                                                         Office of Mergers &
Acquisitions

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._